H.C. Wainwright analyst Swayampakula Ramakanth raised the firm’s price target on Pyxis Oncology to $7 from $4 and keeps a Buy rating on the shares post the Q4 report. The analyst increased the peak penetration rates for PYX-201 to 18% from 15% for all indications based on the “differentiated” safety profile and adjusted operational expenses in 2024 and beyond.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on PYXS:
- Pyxis Oncology Releases Updated Corporate Presentation
- Pyxis Oncology Provides Corporate Update and Reports Financial Results for Fourth Quarter and Full Year 2023
- PYXS Earnings Report this Week: Is It a Buy, Ahead of Earnings?
- Pyxis Oncology Bolsters Board with New Independent Director
- Pyxis Oncology appoints Santhosh Palani to board of directors
